Cytokines in the differentiation therapy of leukemia: From laboratory investigations to clinical applications

Critical Reviews in Clinical Laboratory Sciences

Volumn 42, Issue 5-6, 2005, Pages 473-514

  Leung, K N ^a   Mak, N K ^b   Fung, M C ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

Author keywords

Acute promyelocytic leukemia; Colony stimulating factors; Cytokines; Dendritic cells; Differentiation inducers; Differentiation therapy; Hematopoiesis; Hematopoietic stem cells; Myeloid leukemia; Transcription factors

Indexed keywords

ALPHA INTERFERON; ANTILEUKEMIC AGENT; BETA INTERFERON; BROXURIDINE; COLONY STIMULATING FACTOR; COLONY STIMULATING FACTOR 1; CYCLIC AMP DERIVATIVE; CYTARABINE; DACTINOMYCIN; DAUNORUBICIN; DEXAMETHASONE; DIMETHYL SULFOXIDE; ERYTHROPOIETIN; ESTRADIOL; ETOPOSIDE; GAMMA INTERFERON; HEXAMETHYLENEBISACETAMIDE; HYDROXYUREA; INTERLEUKIN 11; INTERLEUKIN 5; NITROSOGUANIDINE; PHENYLACETIC ACID; PHORBOL 13 ACETATE 12 MYRISTATE; PREDNISONE; STEM CELL FACTOR; THROMBOPOIETIN; TRICHOSTATIN A; TUMOR VACCINE; UNINDEXED DRUG; VINCRISTINE;

BLAST CELL; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL DIFFERENTIATION; CELL LINE; CELL LINEAGE; CELL MATURATION; CELL PROLIFERATION; CYTOKINE RELEASE; ERYTHROCYTE; GRANULOCYTE; HEMATOPOIESIS; HEMATOPOIETIC CELL; HUMAN; IN VITRO STUDY; LABORATORY; LEUKEMIA; LEUKEMOGENESIS; MEGAKARYOCYTE; MOLECULAR CLONING; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; REVIEW; STEM CELL; STEM CELL TRANSPLANTATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; CYTOKINES; DRUG THERAPY, COMBINATION; HEMATOPOIESIS; HUMANS; LEUKEMIA;

EID: 30344453908     PISSN: 10408363     EISSN: None     Source Type: Journal    
DOI: 10.1080/10408360500295154     Document Type: Review

References (223)

1. Friend C, Scher W, Holland JG, Sato T. Hemoglobin synthesis in murine virus-induced leukemic cells in vitro: stimulation of erythroid differentiation by dimethyl sulfoxide. Proc Natl Acad Sci USA 1971; 68: 378-382.
2. Gomez-Vidal JA, Campos J, Marchal JA, Boulaiz H, Gallo MA, Carrillo E, Espinosa A, Aranega A. Actual targets in cytodifferentiation cancer therapy. Curr Top Med Chem 2004; 4: 175-202.
3. Lotem J, Sachs L. Epigenetics wins over genetics: induction of differentiation in tumor cells. Semin Cancer Biol 2002; 12: 339-346.
4. Sell S. Stem cell origin of cancer and differentiation therapy. Crit Rev Oncol Hematol 2004; 51: 1-28.
5. Spira AI, Carducci MA. Differentiation therapy. Curr Opin Pharmacol 2003; 3: 338-343.
6. Zelent A, Petrie K, Chen Z, Lotan R, Lubbert M, Tallman MS, Ohno R, Degos L, Waxman S. Molecular target-based treatment of human cancer: summary of the 10th international conference on differentiation therapy. Cancer Res 2005; 65: 1117-1123.
7. Olsson I, Bergh G, Ehinger M, Gullberg U. Cell differentiation in acute myeloid leukemia. Eur J Haematol 1996; 57: 1-16.
8. Waxman S. Differentiation therapy in acute myelogenous leukemia (non-APL). Leukemia 2000; 14: 491-496.
9. Tallmann MS. Curative therapeutic approaches to APL. Ann Hematol 2004; 83 (Suppl 1): S81-S82.
10. Alexander WS. Cytokines in hematopoiesis. Int Rev Immunol 1998; 16: 651-682.
11. Lotem J, Sachs L. Cytokine control of developmental programs in normal hematopoiesis and leukemia. Oncogene 2002; 21: 3284-3294.
12. Schwarzmeier JD. The role of cytokines in haematopoiesis. Eur J Haematol Suppl 1996; 60: 69-74.
13. Smith C. Hematopoietic stem cells and hematopoiesis. Cancer Control 2003; 10: 9-16.
14. Weissman IL. Translating stem and progenitor cell biology to the clinic: barriers and opportunities. Science 2000; 287: 1442-1446.
15. Metcalf D. Stem cells, pre-progenitor cells and lineage-committed cells: are our dogmas correct? Ann NY Acad Sci 1999; 872: 289-303.
16. Tavian M, Robin C, Coulombel L, Peault B. The human embryo, but not its yolk sac, generates lympho-myeloid stem cells: mapping multipotent hematopoietic cell fate in intraembryonic mesoderm. Immunity 2001; 15: 487-495.
17. Peault B, Oberlin E, Tavian M. Emergence of hematopoietic stem cells in the human embryo. C R Biol 2002; 325: 1021-1026.
18. Leibnitz R. Development of the human immune system. In: Holladay SD, ed. Developmental Immunotoxicology. Pp 21-42. Boca Raton: CRC Press, 2005.
19. Evans T. Developmental biology of hematopoiesis. Hematol Oncol Clin North Am 1997; 11: 1115-1147.
20. Jones RJ, Collector MI, Barber JP, Vala MS, Fackler MJ, May WS, Griffin CA, Hawkins AL, Zehnbauer BA, Hilton J, Colvin OM, Sharkis SJ. Characterization of mouse lymphohematopoietic stem cells lacking spleen colony-forming activity. Blood 1996; 88: 487-491.
21. Barreda DR, Hanington PC, Belosevic M. Regulation of myeloid development and function by colony stimulating factors. Dev Comp Immunol 2004; 28: 509-554.
22. Thomas D, Vadas M, Lopez A. Regulation of haematopoiesis by growth factors - emerging insights and therapies. Expert Opin Biol Ther 2004; 4: 869-879.
23. Metcalf D. The molecular control of hematopoiesis: progress and problems with gene manipulation. Stem Cells 1998; 16: 314-321.
24. Bradley TR Metcalf D. The growth of mouse bone marrow cells in vitro. Aust J Exp Biol Med Sci 1966; 44: 287-299.
25. Pluznik DH, Sachs L. The induction of clones of normal mast cells by a substance from conditioned medium. Exp Cell Res 1966; 43: 553-563.
26. Till JE, McCulloch EA. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res 1961; 14: 213-222.
27. Metcalf D. Colony stimulating factors and hemopoiesis. Ann Acad Med Singapore 1988; 17: 166-170.
28. Morstyn G, Foote MA. Introduction to hematopoietic growth factors - a general overview. In: Morstyn G, Foote MA, Lieschke GJ, eds. Cancer Drug Discovery and Development - Hematopoietic Growth Factors in Oncology: Basic Science and Clinical Therapeutics. Pp 3-10. Totowa, NJ: Humana Press, 2004.
29. Crosier PS, Clark SC. Basic biology of the hematopoietic growth factors. Semin Oncol 1992; 19: 349-361.
30. Youn BS, Mantel C, Broxmeyer HE. Chemokines, chemokine receptors and hematopoiesis. Immunol Rev 2000; 177: 150-174.
31. Sachs L. The control of hematopoiesis and leukemia: from basic biology to the clinic. Proc Natl Acad Sci USA 1996; 93: 4742-4749.
32. Watowich SS, Wu H, Socolovsky M, Klingmuller U, Constantinescu SN, Lodish HF. Cytokine receptor signal transduction and the control of hematopoietic cell development. Annu Rev Cell Dev Biol 1996; 12: 91-128.
33. Vitale M, Bassini A, Secchiero P, Mirandola P, Ponti C, Zamai L, Mariani AR, Falconi M, Azzali G. NK-active cytokines IL-2, IL-12, and IL-15 selectively modulate specific protein kinase C (PKC) isoforms in primary human NK cells. Anat Rec 2002; 266: 87-92.
34. Lentzsch S, Chatterjee M, Gries M, Bommert K, Gollasch H, Dorken B, Bargou RC. PI3-K/AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells. Leukemia 2004; 18: 1883-1890.
35. Rane SG, Reddy EP. JAKs, STATs and Src kinases in hematopoiesis. Oncogene 2002; 21: 3334-3358.
36. Sachs L. The molecular control of blood cell development. Science 1987; 238: 1374-1379.
37. Metcalf D. The colony-stimulating factors: discovery to clinical use. The Florey Lecture, 1991. Philos Trans R Soc Lond B Biol Sci 1991; 333: 147-173.
38. Hara T, Miyajima A. Function and signal transduction mediated by the interleukin 3 receptor system in hematopoiesis. Stem Cells 1996; 14: 605-618.
39. Mangi MH, Newland AC. Interleukin-3 in hematology and oncology: current state of knowledge and future directions. Cytokines Cell Mol Ther 1999; 5: 87-95.
40. Burdach S, Nishinakamura R, Dirksen U, Murray R. The physiologic role of interleukin-3, interleukin-5, granulocyte-macrophage colony-stimulating factor, and the beta c receptor system. Curr Opin Hematol 1998; 5: 177-180.
41. Takeyama K, Ohto H. PBSC mobilization. Transfus Apheresis Sci 2004; 31: 233-243.
42. Lyman SD, Jacobsen SE. c-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. Blood 1998; 91: 1101-1134.
43. Sun Z, Yergeau DA, Tuypens T, Tavernier J, Paul CC, Baumann MA, Tenen DG, Ackerman SJ. Identification and characterization of a functional promoter region in the human eosinophil IL-5 receptor alpha subunit gene. J Biol Chem 1995; 270: 1462-1471.
44. Kimura H, Ishibashi T, Uchida T, Maruyama Y, Friese P, Burstein SA. Interleukin 6 is a differentiation factor for human megakaryocytes in vitro. Eur J Immunol 1990; 20: 1927-1931.
45. Withy RM, Rafield LF, Beck AK, Hoppe H, Williams N, McPherson JM. Growth factors produced by human embryonic kidney cells that influence megakaryopoiesis include erythropoietin, interleukin 6, and transforming growth factor-beta. J Cell Physiol 1992; 153: 362-372.
46. Fisher JW. Erythropoietin: physiology and pharmacology update. Exp Biol Med (Maywood) 2003; 228: 1-14.
47. Nomura S, Ogami K, Kawamura K, Tsukamoto I, Kudo Y, Kanakura Y, Kitamura Y, Miyazaki H, Kato T. Cellular localization of thrombopoietin mRNA in the liver by in situ hybridization. Exp Hematol 1997; 25: 565-572.
48. Wu H, Liu X, Jaenisch R, Lodish HF. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 1995; 83: 59-67.
49. Koury MJ, Sawyer ST, Brandt SJ. New insights into erythropoiesis. Curr Opin Hematol 2002; 9: 93-100.
50. Choi ES, Hokom MM, Chen JL, Skrine J, Faust J, Nichol J, Hunt P. The role of megakaryocyte growth and development factor in terminal stages of thrombopoiesis. Br J Haematol 1996; 95: 227-233.
51. Kaushansky K, Lin N, Grossmann A, Humes J, Sprugel KH, Broudy VC. Thrombopoietin expands erythroid, granulocyte-macrophage, and megakaryocytic progenitor cells in normal and myelo-suppressed mice. Exp Hematol 1996; 24: 265-269.
52. Ogawa M. Differentiation and proliferation of hematopoietic stem cells. Blood 1993; 81: 2844-2853.
53. Keller JR, Bartelmez SH, Sitnicka E, Ruscetti FW, Ortiz M, Gooya JM, Jacobsen SE. Distinct and overlapping direct effects of macrophage inflammatory protein-1 alpha and transforming growth factor beta on hematopoietic progenitor/stem cell growth. Blood 1994; 84: 2175-2181.
54. Fortunel NO, Hatzfeld JA, Monier MN, Hatzfeld A. Control of hematopoietic stem/progenitor cell fate by transforming growth factor-beta. Oncol Res 2003; 13: 445-453.
55. Bedi A, Sharkis SJ. Mechanisms of cell commitment in myeloid cell differentiation. Curr Opin Hematol 1995; 2: 12-21.
56. Juarez J, Bendall L. SDF-1 and CXCR4 in normal and malignant hematopoiesis. Histol Histopathol 2004; 19: 299-309.
57. Lataillade JJ, Domenech J, Le Bousse-Kerdiles MC. Stromal cell-derived factor-1 (SDF-1)/CXCR4 couple plays multiple roles on haematopoietic progenitors at the border between the old cytokine and new chemokine worlds: survival, cell cycling and trafficking. Eur Cytokine Netw 2004; 15: 177-188.
58. Migliaccio G, Migliaccio AR, Adamson JW. In vitro differentiation and proliferation of human hematopoietic progenitors: the effects of interleukins 1 and 6 are indirectly mediated by production of granulocyte-macrophage colony-stimulating factor and interleukin 3. Exp Hematol 1991; 19: 3-10.
59. Schneider E, Ploemacher RE, Navarro S, van BC, Dy M. Characterization of murine hematopoietic progenitor subsets involved in interleukin-3-induced interleukin-6 production. Blood 1991; 78: 329-338.
60. Shabo Y, Lotem J, Sachs L. Induction of genes for transcription factors by normal hematopoietic regulatory proteins in the differentiation of myeloid leukemic cells. Leukemia 1990; 4: 797-801.
61. Lotem J, Shabo Y, Sachs L. The network of hemopoietic regulatory proteins in myeloid cell differentiation. Cell Growth Differ 1991; 2: 421-427.
62. Metcalf D. Lineage commitment of hemopoietic progenitor cells in developing blast cell colonies: influence of colony-stimulating factors. Proc Natl Acad Sci USA 1991; 88: 11310-11314.
63. Wetzler M, Kurzrock R, Taylor K, Spitzer G, Kantarjian H, Baiocchi G, Ku S, Gutterman JU, Talpaz M. Constitutive and induced expression of growth factors in normal and chronic phase chronic myelogenous leukemia Ph1 bone marrow stroma. Cancer Res 1990; 50: 5801-5805.
64. Lisovsky M, Braun SE, Ge Y, Takahira H, Lu L, Savchenko VG, Lyman SD, Broxmeyer HE. Flt3-ligand production by human bone marrow stromal cells. Leukemia 1996; 10: 1012-1018.
65. Wetzler M, Talpaz M, Lowe DG, Baiocchi G, Gutterman JU, Kurzrock R. Constitutive expression of leukemia inhibitory factor RNA by human bone marrow stromal cells and modulation by IL-1, TNF-alpha, and TGF-beta. Exp Hematol 1991: 19: 347-351.
66. Aman MJ, Keller U, Derigs G, Mohamadzadeh M, Huber C, Peschel C. Regulation of cytokine expression by interferon-alpha in human bone marrow stromal cells: inhibition of hematopoietic growth factors and induction of interleukin-1 receptor antagonist. Blood 1994; 84: 4142-4150.
67. Zhu J, Emerson SG. Hematopoietic cytokines, transcription factors and lineage commitment. Oncogene 2002; 21: 3295-3313.
68. Henderson ES, McArthur J. Diagnosis, classification, and assessment of response to treatment. In Henderson ES, Lister TA, Greaves MF, eds. Leukemia. Pp 227-248. Philadelphia: Saunders, 2002.
69. Xie Y, Davies SM, Xiang Y, Robison LL, Ross JA. Trends in leukemia incidence and survival in the United States (1973-1998). Cancer 2003; 97: 2229-2235.
70. Bain B, Catovsky D. Current concerns in haematology. 2: Classification of acute leukaemia. J Clin Pathol 1990; 43: 882-887.
71. Jaffe ES, Harris NL, Diebold J, Muller-Hermelink HK. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. A progress report. Am J Clin Pathol 1999; 111: S8-S12.
72. Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med 1998; 339: 605-615.
73. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-737.
74. Gilliland DG, Jordan CT, Felix CA. The molecular basis of leukemia. Hematology (Am Soc Hematol Educ Program) 2004: 80-97.
75. Guan Y, Gerhard B, Hogge DE. Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood 2003; 101: 3142-3149.
76. Hope KJ, Jin L, Dick JE. Human acute myeloid leukemia stem cells. Arch Med Res 2003; 34: 507-514.
77. Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 2004; 5: 738-743.
78. Larochelle A, Vormoor J, Hanenberg H, Wang JC, Bhatia M, Lapidot T, Moritz T, Murdoch B, Xiao XL, Kato I, Williams DA, Dick JE. Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: implications for gene therapy. Nat Med 1996; 2: 1329-1337.
79. Wang JC, Lapidot T, Cashman JD, Doedens M, Addy L, Sutherland DR, Nayar R, Laraya P, Minden M, Keating A, Eaves AC, Eaves CJ, Dick JE. High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase. Blood 1998; 91: 2406-2414.
80. Huntly BJ, Gilliland DG. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer 2005; 5: 311-321.
81. Cozzio A, Passegue E, Ayton PM, Karsunky H, Cleary ML, Weissman IL. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev 2003; 17: 3029-3035.
82. Huntly BJ, Shigematsu H, Deguchi K, Lee BH, Mizuno S, Duclos N, Rowan R, Amaral S, Curley D, Williams IR, Akashi K, Gilliland DG. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 2004; 6: 587-596.
83. Izraeli S. Leukaemia - a developmental perspective. Br J Haematol 2004; 126: 3-10.
84. Moqattash S, Lutton JD. Leukemia cells and the cytokine network. Proc Soc Exp Biol Med 1998; 219: 8-27.
85. Kiss C, Benko I, Kovacs P. Leukemic cells and the cytokine patchwork. Pediatr Blood Cancer 2004; 42: 113-121.
86. Lang RA, Metcalf D, Cuthbertson RA, Lyons I, Stanley E, Kelso A, Kannourakis G, Williamson DJ, Klintworth GK, Gonda TJ. Transgenic mice expressing a hemopoietic growth factor gene (GM-CSF) develop accumulations of macrophages, blindness, and a fatal syndrome of tissue damage. Cell 1987; 51: 675-686.
87. Testa NG, Dexter TM. Haemopoietic growth factors: their role in acute myeloblastic leukaemia. Br Med Bull 1989; 45: 582-589.
88. Alexander WS, Nicola NA. Hemopoietic growth factor receptor abnormalities in leukemia. Leuk Res 1998; 22: 1097-1111.
89. Goyal RK, Longmore GD. Abnormalities of cytokine receptor signalling contributing to diseases of red blood cell production. Ann Med 1999; 31: 208-216.
90. Boissan M, Feger F, Guillosson JJ, Arock M. c-Kit and c-kit mutations in mastocytosis and other hematological diseases. J Leukoc Biol 2000; 67: 135-148.
91. Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K, Sonoda Y, Fujimoto T, Misawa S. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996; 10: 1911-1918.
92. Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Yagasaki F, Shimazaki C, Akiyama H, Saito K, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Saito H, Ueda R, Ohno R, Naoe T. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001; 97: 2434-2439.
93. Locatelli F, Rossi F. Incidence and pathogenesis of tumor lysis syndrome. Contrib Nephrol 2005; 147: 61-68.
94. Joel SP, Robatiner A. Pharmacology of antileukemic drugs. In: Henderson ES, Lister TA, Greaves MF, eds. Leukemia. Pp 394-440. Philadelphia: Saunders, 2002.
95. Featherstone C, Delaney G, Jacob S, Barton M. Estimating the optimal utilization rates of radiotherapy for hematologic malignancies from a renew of the evidence: Part II - leukemia and myeloma. Cancer 2005; 103: 393-401.
96. Pui CH. Recent advances in the biology and treatment of childhood acute lymphoblastic leukemia. Curr Opin Hematol 1998; 5: 292-301.
97. Negrin RS, Blume KG. Hematopoietic cell transplantation in the leukemias. In: Henderson ES, Lister TA, Greaves MF, eds. Leukemia. Pp 459-484. Philadelphia: Saunders, 2002.
98. Finiewicz KJ, Larson RA. Dose-intensive therapy for adult acute lymphoblastic leukemia. Semin Oncol 1999; 26: 6-20.
99. Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L, Leoni F, Damasio E, Visani G, Papa G. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 1995: 332: 217-223.
100. Khouri IF, Keating M, Korbling M, Przepiorka D, Anderlini P, O'Brien S, Giralt S, Ippoliti C, von WB, Gajewski J, Donato M, Claxton D, Ueno N, Andersson B, Gee A, Champlin R. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817-2824.
101. Choudhury BA, Liang JC, Thomas EK, Flores-Romo L, Xie QS, Agusala K, Sutaria S, Sinha I, Champlin RE, Claxton DF. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. Blood 1999; 93: 780-786.
102. Leszczyniecka M, Roberts T, Dent P, Grant S, Fisher PB. Differentiation therapy of human cancer: basic science and clinical applications. Pharmacol Ther 2001; 90: 105-156.
103. Huberman E, Callaham MF. Induction of terminal differentiation in human promyelocytic leukemia cells by tumor-promoting agents. Proc Natl Acad Sci USA 1979; 76: 1293-1297.
104. Koeffler HP, Bar-Eli M, Territo M. Phorbol diester-induced macrophage differentiation of leukemic blasts from patients with human myelogenous leukemia. J Clin Invest 1980; 66: 1101-1108.
105. Sachs L. The differentiation of myeloid leukaemia cells: new possibilities for therapy. Br J Haematol 1978; 40: 509-517.
106. Cai X, Shen YL, Zhu Q, Jia PM, Yu Y, Zhou L, Huang Y, Zhang JW, Xiong SM, Chen SJ, Wang ZY, Chen Z, Chen GQ. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia 2000; 14: 262-270.
107. Drach J, McQueen T, Engel H, Andreeff M, Robertson KA, Collins SJ, Malavasi F, Mehta K. Retinoic acid-induced expression of CD38 antigen in myeloid cells is mediated through retinoic acid receptor-alpha. Cancer Res 1994; 54: 1746-1752.
108. Kraft AS, William F, Pettit GR, Lilly MB. Varied differentiation responses of human leukemias to bryostatin 1. Cancer Res 1989; 49: 1287-1293.
109. Yamamoto-Yamaguchi Y, Tomida M, Hozumi M, Maurer HR, Okabe T, Takaku F. Combined effects of differentiation-inducing factor and other cytokines on induction of differentiation of mouse myeloid leukemic cells. Jpn J Cancer Res 1989; 80: 115-121.
110. Chan SC, Fung MC, Mak NK, Leung KN. Involvement of interleukin-1 in the differentiation-inducing activity of tumor necrosis factor-a on a murine myeloid leukemia (WEHI-3BJCS). Inter J Oncol 1997; 10: 821-826.
111. Fung MC, Mak NK, Leung KN, Hapel AJ. Decreased expression of J11d antigen during monocytic differentiation of M1 myeloid leukemic cells. Cell Immunol 1992; 141: 121-130.
112. Mak NK, Fung MC, Leung KN, Hapel AJ. Monocytic differentiation of a myelomonocytic leukemic cell (WEHI 3B JCS) is induced by tumour necrosis factor-alpha (TNF-alpha). Cell Immunol 1993; 150: 1-14.
113. Chen F, Rao J, Studzinski GP. Specific association of increased cyclin-dependent kinase 5 expression with monocytic lineage of differentiation of human leukemia HL60 cells. J Leukoc Biol 2000; 67: 559-566.
114. Manfredini R, Trevisan F, Grande A, Tagliafico E, Montanari M, Lemoli R, Visani G, Tura S, Ferrari S, Ferrari S. Induction of a functional vitamin D receptor in all-trans-retinoic acid-induced monocytic differentiation of M2-type leukemic blast cells. Cancer Res 1999; 59: 3803-3811.
115. Rusiniak ME, Yu M, Ross DT, Tolhurst EC, Slack JL. Identification of B94 (TNFAIP2) as a potential retinoic acid target gene in acute promyelocytic leukemia. Cancer Res 2000; 60: 1824-1829.
116. Cutolo M, Villaggio B, Bisso A, Sulli A, Coviello D, Dayer JM. Presence of estrogen receptors in human myeloid monocytic cells (THP-1 cell line). Eur Cytokine Netw 2001; 12: 368-372.
117. Trinchieri G, Kobayashi M, Rosen M, Loudon R, Murphy M, Perussia B. Tumor necrosis factor and lymphotoxin induce differentiation of human myeloid cell lines in synergy with immune Interferon. J Exp Med 1986; 164: 1206-1225.
118. Testa U, Masciulli R, Tritarelli E, Pustorino R, Mariani G, Martucci R, Barberi T, Camagna A, Valtieri M, Peschle C. Transforming growth factor-beta potentiates vitamin D3-induced terminal monocytic differentiation of human leukemic cell lines. J Immunol 1993; 150: 2418-2430.
119. Lopez JA, Newburger PE, Condino-Neto A. The effect of IFN-gamma and TNF-alpha on the eosinophilic differentiation and NADPH oxidase activation of human HL-60 clone 15 cells. J Interferon Cytokine Res 2003; 23: 737-744.
120. El Marjou M, Montalescot V, Buzyn A, Geny B. Modifications in phospholipase D activity and isoform expression occur upon maturation and differentiation in vivo and in vitro in human myeloid cells. Leukemia 2000; 14: 2118-2127.
121. Koeffler HP, Golde DW. Human myeloid leukemia cell lines: a review. Blood 1980; 56: 344-350.
122. Semizarov D, Glesne D, Laouar A, Schiebel K, Huberman E. A lineage-specific protein kinase crucial for myeloid maturation. Proc Natl Acad Sci USA 1998; 95: 15412-15417.
123. Song JH, Kim JM, Kim SH, Kim HJ, Lee JJ, Sung MH, Hwang SY, Kim TS. Comparison of the gene expression profiles of monocytic versus granulocytic lineages of HL-60 leukemia cell differentiation by DNA microarray analysis. Life Sci 2003; 73: 1705-1719.
124. Zheng X, Ravatn R, Lin Y, Shih WC, Rabson A, Strair R, Huberman E, Conney A, Chin KV. Gene expression of TPA induced differentiation in HL-60 cells by DNA microarray analysis. Nucleic Acids Res 2002; 30: 4489-4499.
125. Juan HF, Lin JY Chang WH, Wu CY, Pan TL, Tseng MJ, Khoo KH, Chen ST. Biomic study of human myeloid leukemia cells differentiation to macrophages using DNA array, proteomic, and bioinformatic analytical methods. Electrophoresis 2002; 23: 2490-2504.
126. Larizza L, Magnani I, Beghini A. The Kasumi-1 cell line: A t(8;21)-kit mutant model for acute myeloid leukemia. Leuk Lymphoma 2005; 46: 247-255.
127. Chiu CP, Lee F. IL-6 is a differentiation factor for M1 and WEHI-3B myeloid leukemic cells. J Immunol 1989; 142: 1909-1915.
128. Maeda M, Ichikawa Y. Production of a colony-stimulating factor following differentiation of leukemic myleoblasts to macrophages. J Cell Physiol 1980; 102: 323-331.
129. Parant M, Vinit MA, Damais C, Riveau G, Chedid L. Production of differentiation-stimulating factor for murine leukemic myeloblast line by monocytic cells stimulated by a nonpyrogenic muramyl dipeptide derivative. Exp Hematol 1985; 13: 221-228.
130. Takenaga K, Honma Y, Okabe-Kado J, Hozumi M. Production of differentiation-inhibiting factor in cultured mouse myeloid leukemia cells treated with retinoic acid. Cancer Res 1981; 41: 1948-1953.
131. Tanaka H, Abe E, Miyaura C, Shiina Y, Suda T. 1 alpha,25-dihydroxyvitamin D3 induces differentiation of human promyelocytic leukemia cells (HL-60) into monocyte-macrophages, but not into granulocytes. Biochem Biophys Res Commun 1983; 117: 86-92.
132. Li J, Finch RA, Xiao W, Sartorelli AC. Identification of a repressor of the differentiation of WEHI-3B D-leukemia cells. Exp Cell Res 1998; 242: 274-284.
133. Rice AM, Holtz KM, Karp J, Rollins S, Sartorelli AC. Analysis of the relationship between Scl transcription factor complex protein expression patterns and the effects of LiCl on ATRA-induced differentiation in blast cells from patients with acute myeloid leukemia. Leuk Res 2004; 28: 1227-1237.
134. Du Y, Campbell JL, Nalbant D, Youn H, Bass AC, Cobos E, Tsai S, Keller JR, Williams SC. Mapping gene expression patterns during myeloid differentiation using the EML hematopoietic progenitor cell line. Exp Hematol 2002; 30: 649-658.
135. Ma X, Husain T, Peng H, Lin S, Mironenko O, Maun N, Johnson S, Tuck D, Berliner N, Krause DS, Perkins AS. Development of a murine hematopoietic progenitor complementary DNA microarray using a subtracted complementary DNA library. Blood 2002; 100: 833-844.
136. Valtieri M, Tweardy DJ, Caracciolo D, Johnson K, Mavilio F, Altmann S, Santoli D, Rovera G. Cytokine-dependent granulocytic differentiation. Regulation of proliferative and differentiative responses in a murine progenitor cell line. J Immunol 1987; 138: 3829-3835.
137. Cleaves R, Wang QF, Friedman AD. C/EBPalphap30, a myeloid leukemia oncoprotein, limits G-CSF receptor expression but not terminal granulopoiesis via site-selective inhibition of C/EBP DNA binding. Oncogene 2004; 23: 716-725.
138. O'Donnell LC, Druhan LJ, Avalos BR. Molecular characterization and expression analysis of leucine-rich alpha2-glycoprotein, a novel marker of granulocytic differentiation. J Leukoc Biol 2002; 72: 478-485.
139. Gery S, Gombart AF, Fung YK, Koeffler HP. C/EBPepsilon interacts with retinoblastoma and E2F1 during granulopoiesis. Blood, 2004; 103: 828-835.
140. Kumar A, Lee CM, Reddy EP. c-Myc is essential but not sufficient for c-Myb-mediated block of granulocytic differentiation. J Biol Chem 2003; 278: 11480-11488.
141. Radomska HS, Huettner CS, Zhang P, Cheng T, Scadden DT, Tenen DG. CCAAT/enhancer binding protein alpha is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors. Mol Cell Biol 1998; 18: 4301-4314.
142. Nerlov C, McNagny KM, Doderlein G, Kowenz-Leutz E, Graf T. Distinct C/EBP functions are required for eosinophil lineage commitment and maturation. Genes Dev 1998; 12: 2413-2423.
143. Zhang P, Iwama A, Datta MW, Darlington GJ, Link DC, Tenen DG. Upregulation of interleukin 6 and granulocyte colony-stimulating factor receptors by transcription factor CCAAT enhancer binding protein alpha (C/EBP alpha) is critical for granulopoiesis. J Exp Med 1998; 188: 1173-1184.
144. Bellon T, Perrotti D, Calabretta B. Granulocytic differentiation of normal hematopoietic precursor cells induced by transcription factor PU.1 correlates with negative regulation of the c-myb promoter. Blood 1997; 90: 1828-1839.
145. Kim J, Ogata Y, Feldman RA. Fes tyrosine kinase promotes survival and terminal granulocyte differentiation of factor-dependent myeloid progenitors (32D) and activates lineage-specific transcription factors. J Biol Chem 2003; 278: 14978-14984.
146. Yaron Y, McAdara JK, Lynch M, Hughes E, Gasson JC. Identification of novel functional regions important for the activity of HOXB7 in mammalian cells. J Immunol 2001; 166: 5058-5067.
147. Baron M. An overview of the Notch signalling pathway. Semin Cell Dev Biol 2003; 14: 113-119.
148. Schroeder T, Just U. Notch signalling via RBP-J promotes myeloid differentiation. EMBO J 2000; 19: 2558-2568.
149. Matsuo Y, Drexler HG, Kaneda K, Kojima K, Ohtsuki Y, Hara M, Yasukawa M, Tanimoto M, Orita K. Megakaryoblastic leukemia cell line MOLM-16 derived from minimally differentiated acute leukemia with myeloid/NK precursor phenotype. Leuk Res 2003; 27: 165-171.
150. Lozzio CB, Lozzio BB. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 1975; 45: 321-334.
151. Vainchenker W, Testa U, Guichard J, Titeux M, Breton-Gorius J. Heterogeneity in the cellular commitment of a human leukemic cell line: K 562. Blood Cells 1981; 7: 357-375.
152. Munoz-Alonso MJ, Acosta JC, Richard C, Delgado MD, Sedivy J, Leon J. p21Cip1 and p27Kip1 induce distinct cell cycle effects and differentiation programs in myeloid leukemia cells. J Biol Chem 2005; 280: 18120-18129.
153. Uzunoglu S, Uslu R, Tobu M, Saydam G, Terzioglu E, Buyukkececi F, Omay SB. Augmentation of methylprednisolone-induced differentiation of myeloid leukemia cells by serine/threonine protein phosphatase inhibitors. Leuk Res 1999; 23: 507-512.
154. Gery S, Tanosaki S, Hofmann WK, Koppel A, Koeffler HP. C/EBPdelta expression in a BCR-ABL-positive cell line induces growth arrest and myeloid differentiation. Oncogene 2005; 24: 1589-1597.
155. Takahashi M, Narita M, Ayres F, Satoh N, Abe T, Yanao T, Furukawa T, Toba K, Hirohashi T, Aizawa Y. Cytoplasmic expression of EGFP in dendritic cells transfected with in vitro transcribed mRNA or cellular total RNA extracted from EGFP expressing leukemia cells. Med Oncol 2003; 20: 335-348.
156. Hajas G, Zsiros E, Laszlo T, Hajdu P, Somodi S, Rethi B, Gogolak P, Ludanyi K, Panyi G, Rajnavolgyi E. New phenotypic, functional and electrophysiological characteristics of KG-1 cells. Immunol Lett 2004; 92: 97-106.
157. Hulette BC, Rowden G, Ryan CA, Lawson CM, Dawes SM, Ridder GM, Gerberick GF. Cytokine induction of a human acute myelogenous leukemia cell line (KG-1) to a CD1a+ dendritic cell phenotype. Arch Dermatol Res 2001; 293: 147-158.
158. Li J, Mbow ML, Sun L, Li L, Yang G, Griswold DE, Schantz A, Shealy DJ, Goletz TJ, Wan J, Peritt D. Induction of dendritic cell maturation by IL-18. Cell Immunol 2004; 227: 103-108.
159. Yoshida Y, Sakaguchi H, Ito Y, Okuda M, Suzuki H. Evaluation of the skin sensitization potential of chemicals using expression of co-stimulatory molecules, CD54 and CD86, on the naive THP-1 cell line. Toxicol in Vitro 2003; 17: 221-228.
160. Lindner I, Kharfan-Dabaja MA, Ayala E, Kolonias D, Carlson LM, Beazer-Barclay Y, Scherf U, Hnatyszyn JH, Lee KP. Induced dendritic cell differentiation of chronic myeloid leukemia blasts is associated with down-regulation of BCR-ABL. J Immunol 2003; 171: 1780-1791.
161. Erben U, Thiel E, Bittroff-Leben A, Schoch C, Fichtner I, Durkop H, Notter M. CS-1, a novel c-kithi+ acute myeloid leukemia cell line with dendritic cell differentiation capacity and absent immunogenicity. Int J Cancer 2003; 105: 232-240.
162. Masterson AJ, Sombroek CC, De Gruijl TD, Graus YM, ran d, V, Lougheed SM, van den Eertwegh AJ, Pinedo HM, Scheper RJ. MUTZ-3, a human cell line model for the cytokine-induced differentiation of dendritic cells from CD34+ precursors. Blood 2002; 100: 701-703.
163. Degos L. Differentiating agents in the treatment of leukemia. Leuk Res 1990; 14: 717-719.
164. Hozumi M. Differentiation therapy of leukemia: achievements, limitations and future prospects. Int J Hematol 1998; 68: 107-129.
165. Touw IP, Dong F. Hematopoietic growth factors in leukemia. Pathol Res Pract 1996; 192: 734-742.
166. Ward CJ, Crocker J, Chan SJ, Stockley RA, Burnett D. Changes in the expression of elastase and cathepsin B with differentiation of U937 promonocytes by GMCSF. Biochem Biophys Res Commun 1990; 167: 659-664.
167. Koss A, Lucero G, Koziner B. Granulocyte-colony stimulating factor, granulocyte-macrophage colony stimulating factor and interleukin 4 induce differentiation in the U-937 human monocytic leukemia cell Line. Leuk Lymphoma 1996; 22: 163-171.
168. Goliaei B, Deizadji A. Effects of hyperthermia and granulocyte-macrophage colony-stimulating factor on the differentiation of human leukemic cell line U937. Leuk Res 1998; 22: 705-710.
169. Hozumi M, Tomida M, Yamamoto-Yamaguchi Y, Kasukabe T, Okabe-Kado J, Honma Y, Hayashi M. Protein factors that regulate the growth and differentiation of mouse myeloid leukaemia cells. Ciba Found Symp 1990; 148: 25-33.
170. Senga T, Iwamoto S, Yoshida T, Yokota T, Adachi K, Azuma E, Hamaguchi M, Iwamoto T. LSSIG is a novel murine leukocyte-specific GPCR that is induced by the activation of STAT3. Blood 2003; 101: 1185-1187.
171. Zhang J, Shen B, Li Y, Sun Y. STATS exerts two-way regulation in the biological effects of IL-6 in M1 leukemia cells. Leuk Res 2001; 25: 463-472.
172. Michishita M, Hirayoshi K, Tsuru A, Nakamura N, Yoshida Y, Okuma M, Nagata K. Effects of type-beta 1 transforming growth factor on the proliferation and differentiation of mouse myelomonocytic leukemia cells (M1). Exp Cell Res 1991; 196: 107-113.
173. Kamano H, Tanaka T, Ohnishi H, Kubota Y, Ikeda K, Takahara J, Irino S, Ottalenghi S. Effects of the antisense myb expression on hemin- and erythropoietin-induced erythroid differentiation of K562 cells. Biochem Mol Biol Int 1994; 34: 85-92.
174. Burger PE, Lukey PT, Coetzee S, Wilson EL. Basic fibroblast growth factor modulates the expression of glycophorin A and c-kit and inhibits erythroid differentiation in K562 cells. J Cell Physiol 2002; 190: 83-91.
175. Hodge DR, Li D, Qi SM, Farrar WL. IL-6 induces expression of the Fli-1 proto-oncogene via STAT3. Biochem Biophys Res Commun 2002; 292: 287-291.
176. Peetre C, Gullberg U, Nilsson E, Olsson I. Effects of recombinant tumor necrosis factor on proliferation and differentiation of leukemic and normal hemopoietic cells in vitro. Relationship to cell surface receptor. J Clin Invest 1986; 78: 1694-1700.
177. Mak NK, Leung KN, Fung MC, Hapel AJ. Augmentation of tumor necrosis factor-alpha-induced monocytic differentiation of a myelomonocytic leukemia (WEHI-3B JCS) by pertussis toxin. Immunobiology 1994; 190: 1-12.
178. Leung KN, Mak NK, Fung MC, Hapel AJ. Synergistic effect of IL-4 and TNF-alpha in the induction of monocytic differentiation of a mouse myeloid leukaemic cell line (WEHI-3B JCS). Immunology 1994; 81: 65-72.
179. Kamijo R, Takeda K, Nagumo M, Konno K. Effects of combinations of transforming growth factor-beta 1 and tumor necrosis factor on induction of differentiation of human myelogenous leukemic cell lines. J Immunol 1990; 144: 1311-1316.
180. De BF, Falk LA, Ellingsworth LR, Ruscetti FW, Faltynek CR. Synergy between transforming growth factor-beta and tumor necrosis factor-alpha in the induction of monocytic differentiation of human leukemic cell lines. Blood 1990; 75: 626-632.
181. Brouwer RE, van der HM, Kluin-Nelemans HC, van Zelderen-Bhola S, Willemze R, Falkenburg JH. The generation of dendritic-like cells with increased allostimulatory function from acute myeloid leukemia cells of various FAB subclasses. Hum Immunol 2000; 61: 565-574.
182. Narita M, Takahashi M, Liu A, Ayres F, Satoh N, Abe T, Nikkuni K, Furukawa T, Toba K, Aizawa Y. Generation of dendritic cells from leukaemia cells of a patient with acute promyelocytic leukaemia by culture with GM-CSF, IL-4 and TNF-alpha. Acta Haematol 2001; 106: 89-94.
183. Kharfan-Dabaja M, Ayala E, Lindner I, Cejas PJ, Bahlis NJ, Kolonias D, Carlson LM, Lee KP. Differentiation of acute and chronic myeloid leukemic blasts into the dendritic cell lineage: analysis of various differentiation-inducing signals. Cancer Immunol Immunother 2005; 54: 25-36.
184. Gabriele L, Borghi P, Rozera C, Sestili P, Andreotti M, Guarini A, Montefusco E, Foa R, Belardelli F. IFN-alpha promotes the rapid differentiation of monocytes from patients with chronic myeloid leukemia into activated dendritic cells tuned to undergo full maturation after LPS treatment. Blood 2004; 103: 980-987.
185. Liebermann DA, Hoffman-Liebermann B. Proto-oncogene expression and dissection of the myeloid growth to differentiation developmental cascade. Oncogene 1989; 4: 583-592.
186. Larsson LG, Pettersson M, Oberg F, Nilsson K, Luscher B. Expression of mad, mxil, max and c-myc during induced differentiation of hematopoietic cells: opposite regulation of mad and c-myc. Oncogene 1994; 9: 1247-1252.
187. Zervos AS, Gyuris J, Brent R. Mxi1, a protein that specifically interacts with Max to bind Myc-Max recognition sites. Cell 1993; 72: 223-232.
188. Liu J, Clegg CH, Shoyab M. Regulation of EGR-1, c-jun, and c-myc gene expression by oncostatin M. Cell Growth Differ 1992; 3: 307-313.
189. Sjin RM, Lord KA, Abdollahi A, Hoffman B, Liebermann DA. Interleukin-6 and leukemia inhibitory factor induction of JunB is regulated by distinct cell type-specific cis-acting elements. J Biol Chem 1999; 274: 28697-28707.
190. Nguyen HQ, Hoffman-Liebermann B, Liebermann DA. The zinc finger transcription factor Egr-1 is essential for and restricts differentiation along the macrophage lineage. Cell 1993; 72: 197-209.
191. Xia Q, Wang HX, Wang J, Zhang JY, Liu BY, Li AL, Lv M, Hu MR, Yu M, Feng JN, Yang SC, Zhang XM, Shen BF. Proteomic analysis of interleukin 6-induced differentiation in mouse myeloid leukemia cells. Int J Biochem Cell Biol 2005; 37: 1197-1207.
192. Matsuda T, Hirano T. Association of p72 tyrosine kinase with Stat factors and its activation by interleukin-3, interleukin-6, and granulocyte colony-stimulating factor. Blood 1994; 83: 3457-3461.
193. Sakurai T, Yamada T, Kihara-Negishi F, Teramoto S, Sato Y. Izawa T, Oikawa T. Effects of overexpression of the Ets family transcription factor TEL on cell growth and differentiation of K562 cells. Int J Oncol 2003; 22: 1327-1333.
194. Mangan JK, Rane SG, Kang AD, Amanullah A, Wong BC, Reddy EP. Mechanisms associated with IL-6-induced up-regulation of Jak3 and its role in monocytic differentiation. Blood 2004; 103: 4093-4101.
195. Hirano T, Ishihara K, Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 2000; 19: 2548-2556.
196. Drexler HG, Zaborski M, Quentmeier H. Cytokine response profiles of human myeloid factor-dependent leukemia cell lines. Leukemia 1997; 11: 701-708.
197. Katagiri T, Miyazawa K, Nishimaki J, Yaguchi M, Kawanishi Y, Ohyashiki K. Combination of granulocyte colony-stimulating factor and low-dose cytosine arabinoside further enhances myeloid differentiation in leukemia cells in vitro. Leuk Lymphoma 2000; 39: 173-184.
198. Glasow A, Prodromou N, Xu K, von Lindern M, Zelent A. Retinoids and myelomonocytic growth factors cooperatively activate RARA and induce human myeloid leukemia cell differentiation via MAP kinase pathways. Blood 2005; 105: 341-349.
199. Fenaux P, De Botton S. Retinoic acid syndrome. Recognition, prevention and management. Drug Saf 1998; 18: 273-279.
200. Hsu HC, Tsai WH, Chen PG, Hsu ML, Ho CK, Wang SY. In vitro effect of granulocyte-colony stimulating factor and all-trails retmoic acid on the expression of inflammatory cytokines and adhesion molecules in acute promyelocytic leukemic cells. Eur J Haematol 1999; 63: 11-18.
201. Camarasa MV, Castro-Galache MD, Carrasco-Garcia E, Garcia-Morales P, Saceda M. Ferragut JA. Differentiation and drug resistance relationships in leukemia cells. J Cell Biochem 2005; 94: 98-108.
202. Lawson ND, Krause DS, Berliner N. Normal neutrophil differentiation and secondary granule gene expression in the EML and MPRO cell lines. Exp Hematol 1998; 26: 1178-1185.
203. Kishi K, Toba K, Azegami T, Tsukada N, Uesugi Y, Masuko M, Niwano H, Hashimoto S, Sakaue M, Furukawa T, Koike T, Takahashi H, Maekawa T, Abe T, Aizawa Y. Hematopoietic cytokine-dependent differentiation to eosinophils and neutrophils in a newly established acute promyelocytic leukemia cell line with t(15;17). Exp Hematol 1998; 26: 135-142.
204. Chelbi-Alix MK, Bobe P, Benoit G, Canova A, Pine R. Arsenic enhances the activation of Stat1 by interferon gamma leading to synergistic expression of IRF-1. Oncogene 2003; 22: 9121-9130.
205. Moldenhauer A, Nociari M, Lam G, Salama A, Rafii S, Moore MA. Tumor necrosis factor alpha-stimulated endothelium: an inducer of dendritic cell development from hematopoietic progenitors and myeloid leukemic cells. Stem Cells 2004; 22: 144-157.
206. Vedantham S, Gamliel H, Golomb HM. Mechanism of interferon action in hairy cell leukemia: a model of effective cancer biotherapy. Cancer Res 1992; 52: 1056-1066.
207. Bedi A, Griffin CA, Barber JP, Vala MS, Hawkins AL, Sharkis SJ, Zehnbauer BA, Jones RJ. Growth factor-mediated terminal differentiation of chronic myeloid leukemia. Cancer Res 1994; 54: 5535-5538.
208. Glaspy JA. Hematopoietic management in oncology practice. Part 1. Myeloid growth factors. Oncology (Williston Park) 2003; 17: 1593-1603.
209. Nimubona S, Grulois I, Bernard M, Drenou B, Godard M, Fauchet R, Lamy T. Complete remission in hypoplastic acute myeloid leukemia induced by G-CSF without chemotherapy: report on three cases. Leukemia 2002; 16: 1871-1873.
210. Lanza F, Rigolin GM, Castagnari B, Moretti S, Castoldi G. Potential clinical applications of rhGM-CSF in acute myeloid leukemia based on its biologic activity and receptor interaction. Haematologica 1997; 82: 239-245.
211. Boyer MW, Waller EK, Bray RA, Unangst T, Johnson TS, Phillips C, Jurickova I, Winton EF, Yeager AM. Cytokine upregulation of the antigen presenting function of acute myeloid leukemia cells. Leukemia 2000; 14: 412-418.
212. Paquette RL, Hsu N, Said J, Mohammed M, Rao NP, Shih G, Schiller G, Sawyers C, Glaspy JA. Interferon-alpha induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivo. Leukemia 2002; 16: 1484-1489.
213. Roddie PH, Horton Y, Turner ML. Primary acute myeloid leukaemia blasts resistant to cytokine-induced differentiation to dendritic-like leukaemia cells can be forced to differentiate by the addition of bryostatin-1. Leukemia 2002; 16: 84-93.
214. Braun S, Gerhartz HH, Schmetzer HM. Lymphokine-activated killer (LAK) cells and cytokines synergize to kill clonal cells in acute myeloid leukemia (AML) in vitro. Haematologia (Budap) 2000; 30: 271-288.
215. Pospisilova D, Bororickova J, Polouckova A, Spisek R, Sediva A, Hrusak O, Stary J, Bartunkova J. Generation of functional dendritic cells for potential use in the treatment of acute lymphoblastic leukemia. Cancer Immunol Immunother 2002; 51: 72-78.
216. Chao JR, Wang JM, Lee SF, Peng HW, Lin YH, Chou CH, Li JC, Huang HM, Chou CK, Kuo ML, Yen JJ, Yang-Yen HF. mcl-1 is an immediate-early gene activated by the granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling pathway and is one component of the GM-CSF viability response. Mol Cell Biol 1998; 18: 4883-4898.
217. Ikeda H, Kanakura Y, Furitsu T, Kitayama H, Sugahara H, Nishiura T, Karasuno T, Tomiyama Y, Yamatodani A, Kanayama Y. Changes in phenotype and proliferative potential of human acute myeloblastic leukemia cells in culture with stem cell factor. Exp Hematol 1993; 21: 1686-1694.
218. Buhring HJ, Herbst R, Kostka G, Bossenmaier B, Bartke I, Kropshofer H, Kalbacher H, Busch FW, Muller CA, Schlessinger J. Modulation of p145c-kit function in cells of patients with acute myeloblastic leukemia. Cancer Res 1993; 53: 4424-4431.
219. Bergamaschi G, Carlo-Stella C, Cazzola M, de Fazio P, Pedrazzoli P, Peverali FA, Della Valle G. Tumor necrosis factor alpha down-regulates c-myc mRNA expression and induces in vitro monocytic differentiation in fresh blast cells from patients with acute myeloblastic leukemia. Leukemia 1990; 4: 426-430.
220. Hirai H, Shimazaki C, Yamagata N, Goto H, Inaba T, Kikuta T, Sumikuma T, Sudo Y, Ashihara E, Fujita N, Hibi S, Imashuku S, Ito E, Nakagawa M. Effects of thrombopoietin (c-mpl ligand) on growth of blast cells from patients with transient abnormal myelopoiesis and acute myeloblastic leukemia. Eur J Haematol 1997; 59: 38-46.
221. Cignetti A, Bryant E, Allione B, Vitale A, Foa R, Cheever MA. CD34(+) acute myeloid and lymphoid leukemic blasts can be induced to differentiate into dendritic cells. Blood 1999; 94: 2048-2055.
222. Graeber TG, Shuai K. Rapid gene repression triggered by interleukin-6 at the onset of monocyte differentiation. Biochem Biophys Res Commun 2000; 267: 863-869.
223. Piekorz RP, Rinke R, Gouilleux F, Neumann B, Groner B, Hocke GM. Modulation of the activation status of Stat5a during LIF-induced differentiation of MI myeloid leukemia cells. Biochim Biophys Acta 1998; 1402: 313-323.